Boston Scientific Corporation $BSX Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 54.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,036 shares of the medical equipment provider’s stock after selling 12,074 shares during the period. Atria Wealth Solutions Inc.’s holdings in Boston Scientific were worth $1,070,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in Boston Scientific by 15.4% in the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 3,932 shares during the last quarter. MRA Advisory Group purchased a new stake in Boston Scientific in the second quarter valued at $273,000. Bank of New Hampshire boosted its holdings in Boston Scientific by 552.0% in the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after purchasing an additional 16,699 shares during the last quarter. NS Partners Ltd boosted its holdings in Boston Scientific by 1.6% in the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after purchasing an additional 5,704 shares during the last quarter. Finally, New England Research & Management Inc. purchased a new stake in Boston Scientific in the second quarter valued at $1,133,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on BSX. UBS Group upped their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Raymond James Financial increased their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Wells Fargo & Company increased their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Truist Financial increased their target price on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Finally, Leerink Partners increased their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $120.71.

Boston Scientific Stock Up 1.5%

BSX opened at $99.20 on Friday. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average price of $101.29 and a 200 day moving average price of $101.74. The company has a market cap of $146.99 billion, a PE ratio of 59.05, a price-to-earnings-growth ratio of 2.35 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the firm earned $0.62 EPS. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $17,972,457 in the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.